Cytochrome P450 enzymes as drug targets in human disease.
CYP inhibition
CYP3A4
Cytochrome P450 (CYP)
cytochrome P450
cytochrome P450 function
drug development/discovery
Journal
Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
accepted:
02
10
2023
received:
29
08
2023
revised:
19
09
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
aheadofprint
Résumé
Although the mention of cytochrome P450 (P450, CYP) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential but in certain disease states it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in us, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e. g. P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1.
Identifiants
pubmed: 37793784
pii: dmd.123.001431
doi: 10.1124/dmd.123.001431
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Society for Pharmacology and Experimental Therapeutics.